In vitro and in vivo neuroprotection by γ-glutamylcysteine ethyl ester against MPTP: Relevance to the role of glutathione in Parkinson's disease

Neuroscience Letters

Volumn 402, Issue 1-2, 2006, Pages 137-141

  Chinta, Shankar J ^a   Rajagopalan, Subramanian ^a   Butterfield, D Allan ^b   Andersen, Julie K ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Glutamylcysteinyl ethyl ester; Glutathione; MPTP; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ESTER DERIVATIVE; GAMMA GLUTAMYLCYSTEINE; GLUTATHIONE; LIPID; SCAVENGER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLUTATHIONE METABOLISM; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; BUTHIONINE SULFOXIMINE; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPEPTIDES; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ENZYME INHIBITORS; GLUTATHIONE; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NEUROPROTECTIVE AGENTS; RATS; TYROSINE 3-MONOOXYGENASE;

EID: 33646796739     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.03.056     Document Type: Article

References (25)

1. Abello P.A., Fidler S.A., and Buchman T.G. Thiol reducing agents modulate induced apoptosis in porcine endothelial cells. Shock 2 2 (1994) 79-83
2. Andersen J.K., Mo J.Q., Hom D.G., Lee F.Y., Harnish P., Hamill R.W., and McNeill T.H. Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on the murine nigrostriatal neurons. J. Neurochem. 67 5 (1996) 2164-2171
3. Bahat-Stroomza M., Gilgun-Sherki Y., Offen D., Panet H., Saada A., Krool-Galron N., Barzilai A., Atlas D., and Melamed E. A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease. Eur. J. Neurosci. 21 3 (2005) 637-646
4. Boyd-Kimball D., Sultana R., Abdul H.M., and Butterfield D.A. Gamma-glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against Abeta(1-42)-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J. Neurosci. Res. 79 5 (2005) 700-706
5. Chol M., Nevo N., Cherqui S., Antignac C., and Rustin P. Glutathione precursors replenish decreased glutathione pool in cystinotic cell lines. Biochem. Biophys. Res. Commun. 324 1 (2004) 231-235
6. Drake J., Kanski J., Varadarajan S., Tsoras M., and Butterfield D.A. Elevation of brain glutathione by gamma-glutamylcysteine ethyl ester protects against peroxynitrite-induced oxidative stress. J. Neurosci. Res. 68 6 (2002) 776-784
7. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55 (1996) 259-272
8. Gilgun-Sherki Y., Melamed E., and Offen D. Oxidative stress induced neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 40 (2001) 959-975
9. Hsu M., Srinivas B., Kumar J., Subramanian R., and Andersen J. Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease. J. Neurochem. 92 5 (2005) 1091-1103
10. Jain A., Martensson J., Stole E., Auld P.A., and Meister A. Glutathione deficiency leads to mitochondrial damage in brain. Proc. Natl. Acad. Sci. U.S.A. 88 5 (1991) 1913-1917
11. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13 Suppl. 1 (1998) 24-34
12. Jha N., Jurma O., Lalli G., Liu Y., Pettus E.H., Greenamyre J.T., Liu R.M., Forman H.J., and Andersen J.K. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J. Biol. Chem. 275 34 (2000) 26096-26101
13. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., and Andersen J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo. A novel therapy for Parkinson's disease. Neuron 37 (2003) 899-909
14. Liu H., Wang H., Shenvi S., Hagen T.M., and Liu R.M. Glutathione metabolism during aging and in Alzheimer disease. Ann. N. Y. Acad. Sci. 1019 (2004) 346-349
15. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., Cory-Slechta D.A., and Di Monte D.A. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 10 2 (2002) 119-127
16. Meister A. Glutathione-ascorbic acid antioxidant system in animals. J. Biol. Chem. 269 13 (1994) 9397-9400
17. Meister A., and Andersson M. Glutathione. Annu. Rev. Biochem. (1983) 711-760
18. Pearce R.K., Owen A., Daniel S., Jenner P., and Marsden C.D. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural. Trans. 104 6-7 (1997) 661-677
19. Perry T.L., Godin D.V., and Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency?. Neurosci. Lett. 33 3 (1982) 305-310
20. Perry T.L., and Yong V.W. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67 3 (1986) 269-274
21. Prasad K.N., Carvalho E., Kentroti S., Edwards-Prasad J., Freed C., and Vernadakis A. Establishment and characterization of immortalized clonal cell lines from fetal rat mesencephalic tissue. In Vitro Cell. Dev. Biol. Anim. 30A (1994) 596-603
22. Sechi G., Deledda M.G., Bua G., Satta W.M., Deiana G.A., Pes G.M., and Rosati G. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 20 7 (1996) 1159-1170
23. Sen C.K. Redox signaling and the emerging therapeutic potential of thiol antioxidants. Biochem. Pharmacol. 55 11 (1998) 1747-1758
24. Trounce I.A., Kim Y.L., Jun A.S., and Wallace D.C. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol. 264 (1996) 484-509
25. Wullner U., Loschmann P.A., Schulz J.B., Schmid A., Dringen R., Eblen F., Turski L., and Klockgether T. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones. Neuroreport 7 4 (1996) 921-923